Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil, Training and Research Hospital, Diyarbakir, Turkey.
SBÜ, Diyarbakır Gazi Yaşargil Eğitim Ve Araştırma Hastanesi, Nükleer Tıp Kliniği, Üçkuyular Mahallesi, Kayapınar, 21070, Diyarbakır, Turkey.
Ann Nucl Med. 2023 Sep;37(9):517-527. doi: 10.1007/s12149-023-01854-9. Epub 2023 Jun 18.
The aim of this study was to determine the prognostic role of volumetric parameters and Pro-PET scores obtained from Ga-prostate-specific membrane antigen (PSMA) PET/CT and F-FDG PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving taxane therapy.
The study included 71 patients who underwent simultaneous PSMA and F-FDG PET/CT imaging between January 2019 and January 2022, had a Pro-PET score of 3-5 and had received taxane therapy after imaging. F-FDG tumor volume (TV-F) and PSMA tumor volume (TV-P) values of the lesions and total lesion glycolysis (TL-G) and total lesion PSMA (TL-P) values of the lesions were calculated on both imaging studies and the effects of these parameters on overall survival (OS) were investigated.
The median age of the patients included herein was 71 years (56-89) and the median prostate-specific antigen (PSA) level was 16.4 (0.01-1852 ng/dL). According to the Kaplan-Meier survival analysis, TTV-P ≥ 78.5, TTL-P ≥ 278.8, TTV-F ≥ 94.98, TTL-G ≥ 458.3, TTV-P + F ≥ 195.45, TTL-G + P ≥ 855.78, lymph node (L)TV-FDG ≥ 3.4, LFDG-SUVmax ≥ 3.2, LFDG-SUVmean ≥ 2.25, LFDG-SUVpeak ≥ 2.55, and bone (B)TV-F ≥ 51.15 values were found to be prognostic factors in predicting short OS. Multivariate Cox regression analysis showed that a Vscore ≥ 3 (95% confidence interval [CI]: 7.069-98.251, p < 0.001) and TTL-G + P ≥ 855.78 (95% CI: 4.878-1037.860, p = 0.006) were found to be independent prognostic factors in predicting short OS.
Volumetric parameters and Pro-PET scores obtained from Ga-PSMA PET/CT and F-FDG PET/CT imaging have been shown to have an impact on OS in patients with mCRPC receiving taxane therapy.
本研究旨在确定从 Ga-前列腺特异性膜抗原（PSMA）PET/CT 和 F-FDG PET/CT 获得的体积参数和 Pro-PET 评分在接受紫杉烷治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中的预后作用。
本研究纳入了 2019 年 1 月至 2022 年 1 月期间同时接受 PSMA 和 F-FDG PET/CT 成像检查、Pro-PET 评分为 3-5 分且成像后接受紫杉烷治疗的 71 例患者。计算病变的 F-FDG 肿瘤体积（TV-F）和 PSMA 肿瘤体积（TV-P）值以及病变的总肿瘤糖酵解（TL-G）和总病变 PSMA（TL-P）值，并研究这些参数对总生存（OS）的影响。
本研究中患者的中位年龄为 71 岁（56-89 岁），中位前列腺特异性抗原（PSA）水平为 16.4（0.01-1852ng/dL）。根据 Kaplan-Meier 生存分析，TTV-P≥78.5、TTL-P≥278.8、TTV-F≥94.98、TTL-G≥458.3、TTV-P+F≥195.45、TTL-G+P≥855.78、淋巴结（L）FDG-TV≥3.4、LFDG-SUVmax≥3.2、LFDG-SUVmean≥2.25、LFDG-SUVpeak≥2.55 和骨（B）FDG-TV≥51.15 值被发现是预测短期 OS 的预后因素。多变量 Cox 回归分析显示，Vscore≥3（95%置信区间[CI]：7.069-98.251，p<0.001）和 TTL-G+P≥855.78（95%CI：4.878-1037.860，p=0.006）是预测短期 OS 的独立预后因素。
从 Ga-PSMA PET/CT 和 F-FDG PET/CT 成像获得的体积参数和 Pro-PET 评分已被证明对接受紫杉烷治疗的 mCRPC 患者的 OS 有影响。
